Single-blind comparison of venlafaxine and nortriptyline in elderly major depression

Journal of Clinical Psychopharmacology

Volumn 23, Issue 1, 2003, Pages 21-26

  Gastó, Cristóbal ^a   Navarro, Víctor ^a,b   Marcos, Teodoro ^a   Portella, María J ^a   Torra, Mercè ^a   Rodamilans, Miquel ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; LORAZEPAM; NORTRIPTYLINE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING; TREATMENT OUTCOME; TREMOR; URINARY DYSFUNCTION; VERTIGO; VISUAL DISORDER; XEROSTOMIA;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NORTRIPTYLINE; PSYCHIATRIC STATUS RATING SCALES; SINGLE-BLIND METHOD;

EID: 0037308176     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200302000-00004     Document Type: Article

References (30)

1. NIH Consensus Development Panel on Depression in Late Life. Diagnosis and treatment of depression in late life. JAMA 1992;268: 1018-1024.
2. Montgomery SA. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:119-126.
3. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000;57:503-509.
4. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-4497.
5. Schweitzer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-108.
6. Benedictis E. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Clin Psychopharmacol 2000;14:61-66.
7. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241.
8. Schweitzer E, Weise C, Clary C, Fox I, Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11:233-236.
9. Benkert O, Grunder G, Wetzel H, Hackett D. A randomized, double blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996;30:441-51.
10. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55(9 Suppl. A):62-68.
11. Richelson E. Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-1081.
12. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(3 Suppl 2):37-50.
13. Staab JP, Evans DL. Efficacy of venlafaxine in geriatric depression. Depress Anxiety 2000;12(Suppl. 1):63-68.
14. Heeren TJ, Derksen P, Heycop Ten ham BF, Van Gent PPJ. Treatment, outcome and predictors of response in elderly depressed inpatients. Br J Psychiatry 1997;170:436-440.
15. Reynolds CF III, Perel JM, Frank E, Cornes C, Miller MD, Houck PR. Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry 1999;156:1177-1181.
16. Endicott J, Spitzer RJ. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978;35:837-844.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
18. Carney MPW, Roth M, Garside RF. The diagnosis of depressive syndromes and the prediction of ECT response. Br J Psychiatry 1965; 111:659-674.
19. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
20. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. Acta Psychiatr Scand 1987;76(Suppl. 334): 1-100.
21. Grunder G, Wetzel H, Schlosser R, Benkert O. Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure: assessment by automatic 24-hour monitoring. Pharmacopsychiatry 1996;29:72.78.
22. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:735-739.
23. Mulsant BH, Pollock BG, Nebes RD, Miller MD, Litlle JT, Stack J. A double-blind randomised comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 1999;60(Suppl. 20):16-20.
24. Navarro V, Gastó C, Torres X, Marcos T, Pintor L. Citalopram versus nortriptyline in late-life depression: a 12-week randomized singleblind study. Acta Psychiatr Scand 2001;103:1-6.
25. Mahapatra SN, Hackett D. A randomised, double-blind, parallel group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 1997;51:209-213.
26. Smeraldi E, Rizzo F, Crespi G. Double-blind, randomised study of venlafaxine, clomipramine, and trazodone in geriatric patients with major depression. Primary Care Psychiatry 1998;4:189-195.
27. Dierick M. An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 1996; 8:169-78.
28. Khan A, Rudolph R, Baumel B, Fengurson J, Ryan P, Shrivastava R. Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharm Bull 1995;31:753-758.
29. Amore M, Ricci M, Zanardi R, Perez J, Ferrari G. Long-term treatment of geropsychiatiic depressed patients with venlafaxine. J Affect Disord 1997;46:293-296.
30. Zimmer B, Kant R, Zeiler D, Brilmyer M. Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders. Int J Psychiatry Med 1997;27:353-364.